1-5 of 5
Richard Bryce
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View article titled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5818–5827.
https://doi.org/10.1158/1078-0432.CCR-21-1584
Published: 01 November 2021
View article titled, Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer in another window
Journal Articles

Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib

Gary A. Ulaner, Cristina Saura, Sarina A. Piha-Paul, Ingrid Mayer, David Quinn, Komal Jhaveri, Ben Stone, Seta Shahin, Grace Mann, Melanie Dujka, Richard Bryce, Funda Meric-Bernstam, David B. Solit, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7381–7387.
https://doi.org/10.1158/1078-0432.CCR-19-1658
Published: 13 December 2019
View article titled, Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
Open the PDF for Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib in another window
Journal Articles

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Dhivya R. Sudhan, Luis J. Schwarz, Angel Guerrero-Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González Ericsson, Melinda Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 771–783.
https://doi.org/10.1158/1078-0432.CCR-18-1131
Published: 15 January 2019
View article titled, Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial
Open the PDF for Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial in another window
Includes: Supplementary data
Journal Articles

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P. Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J. Pluard, Carey Anders, Polly Ann Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C. Banks, Richard B. Lanman, Richard Bryce, Alshad S. Lalani, John Pfeifer, Daniel F. Hayes, Mark Pegram, Kimberly Blackwell, Philippe L. Bedard, Hussam Al-Kateb, Matthew J.C. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5687–5695.
https://doi.org/10.1158/1078-0432.CCR-17-0900
Published: 01 October 2017
View article titled, Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer
Open the PDF for Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer in another window
Includes: Supplementary data